Cargando…
Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer
Ovarian cancer is the leading cause of death from gynecologic malignancy in the Western world. This is due, in part, to the fact that despite standard treatment of surgery and platinum/paclitaxel most patients recur with ultimately chemoresistant disease. Ovarian cancer is a unique form of solid tum...
Autores principales: | Emmings, Edith, Mullany, Sally, Chang, Zenas, Landen, Charles N., Linder, Stig, Bazzaro, Martina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337358/ https://www.ncbi.nlm.nih.gov/pubmed/30626133 http://dx.doi.org/10.3390/ijms20010229 |
Ejemplares similares
-
Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers
por: Zhang, Xiaonan, et al.
Publicado: (2020) -
Dienone Compounds: Targets and Pharmacological Responses
por: Bazzaro, Martina, et al.
Publicado: (2020) -
Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries
por: Zhang, Xiaonan, et al.
Publicado: (2021) -
Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review
por: Cornelison, Robert, et al.
Publicado: (2017) -
Chemoresistance and targeted therapies in ovarian and endometrial cancers
por: Brasseur, Kevin, et al.
Publicado: (2016)